It might seem like luck for a company to trip over a multi-billion dollar COVID treatment already lurking in its pipeline – but perhaps not so much when that company, Gilead, has been at the leading edge of antiviral R&D for decades.
Targeted business development acquisitions, improvements in R&D and operating performance, and a strengthened post-demerger balance sheet are creating new capacity and flexibility for GSK to invest in growth and innovation for patients and shareholders.
A requirement under the U.S. law known as Obamacare that private insurance plans cover drugs that prevent HIV infection at no cost to patients violates both federal law and the Constitution, a federal judge ruled on Wednesday, siding with conservative lawyers who had challenged the measure on religious grounds.
Gilead’s total revenue for Q2 increased 1% to $6.3 billion compared to Q2 in 2021. Overall, the company exceeded both its own expectations and the predictions of market analysts for the second quarter.